Comparison of Low-Intensity Warfarin Therapy with Conventional-Intensity Warfarin Therapy for Long-Term Prevention of Recurrent Venous Thromboembolism
The DOI matches its Crossref record, with a small difference in title or year; 12 of the 12 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Warfarin is very effective in preventing recurrent venous thromboembolism but is also associated with a substantial risk of bleeding. After three months of conventional warfarin therapy, a lower dose of anticoagulant medication may result in less bleeding and still prevent recurrent venous thromboembolism. METHODS: We conducted a randomized, double-blind study, in which 738 patients who had completed three or more months of warfarin therapy for unprovoked venous thromboembolism were randomly assigned to continue warfarin therapy with a target international normalized ratio (INR) of 2.0 to 3.0 (conventional intensity) or a target INR of 1.5 to 1.9 (low intensity). Patients were followed for an average of 2.4 years. RESULTS: Of 369 patients assigned to low-intensity therapy, 16 had recurrent venous thromboembolism (1.9 per 100 person-years), as compared with 6 of 369 assigned to conventional-intensity therapy (0.7 per 100 person-years; hazard ratio, 2.8; 95 percent confidence interval, 1.1 to 7.0). A major bleeding episode occurred in nine patients assigned to low-intensity therapy (1.1 events per 100 person-years) and eight patients assigned to conventional-intensity therapy (0.9 event per 100 person-years; hazard ratio, 1.2; 95 percent confidence interval, 0.4 to 3.0). There was no significant difference in the frequency of overall bleeding between the two groups (hazard ratio, 1.3; 95 percent confidence interval, 0.8 to 2.1). CONCLUSIONS: Conventional-intensity warfarin therapy is more effective than low-intensity warfarin therapy for the long-term prevention of recurrent venous thromboembolism. The low-intensity warfarin regimen does not reduce the risk of clinically important bleeding.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We identified 1 RCT 317 to inform this recommendation.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [316]
In the citing paper
“However, it should be noted that patients considered to have a ' high risk of bleeding ' were excluded from the randomized trial described in the analysis above. 316”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [316]
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181 · cited 1×
“[7] Hazard ratios associated with low-intensity therapy as compared with conventional-intensity therapy (with 95 percent confidence intervals) and log-rank tests were used to compare the treatment groups.”
MethodNonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Mutation in blood coagulation factor V associated with resistance to activated protein C
Bertina, R. M., Koeleman, B. P. C., Koster, T., Rosendaal, F. R., Dirven, R. J., de Ronde, H., van der Velden, P. A., & Reitsma, P. H. (1994) · Nature · doi:10.1038/369064a0 · Cited by 3,783
Poort, Sr., Rosendaal, F., Reitsma, P., & Bertina, R. (1996) · Blood · doi:10.1182/blood.v88.10.3698.bloodjournal88103698 · Cited by 3,079 · cited 1×
“Assays for factor V Leiden [4] and the G20210A mutation in the prothrombin gene [5] were performed in a central laboratory by technologists who were unaware of the patient's treatment-group assignment and clinical course.”
MethodOral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range
Hirsh, J., Dalen, J. E., Anderson, D. R., Poller, L., Bussey, H., Ansell, J., & Deykin, D. (2001) · Chest · doi:10.1378/chest.119.1_suppl.8s · Cited by 1,804 · cited 1×
“0 per 100 patient-years among those assigned to low-intensity therapy, [6] an average of 2.”
BackgroundSelf-citationKearon, C., Gent, M., Hirsh, J., Weitz, J., Kovacs, M. J., Anderson, D. R., Turpie, A. G., Green, D., Ginsberg, J. S., Wells, P., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903253401201 · Cited by 1,072 · cited 5×
“As in other studies, [2,10] factor V Leiden and prothrombin-gene mutations were not associated with a higher risk of recurrent thromboembolism, although all patients in our study were treated with anticoagulant therapy.”
BackgroundResultInfluentialSelf-citationNatural History of Venous Thromboembolism
Kearon, C. (2003) · Circulation · doi:10.1161/01.cir.0000078464.82671.78 · Cited by 1,048
Self-citationLong-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism
Ridker, P. M., Goldhaber, S. Z., Danielson, E., Rosenberg, Y., Eby, C. S., Deitcher, S. R., Cushman, M., Moll, S., Kessler, C. M., Elliott, C. G., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035029 · Cited by 808 · cited 2×
“Collectively, the results of our study and the three other trials that have evaluated extended treatment of patients who have had unprovoked venous thromboembolism [2,3,9] suggest that low-intensity anticoagulant therapy reduces the risk of recurrent thrombosis by about 75 percent, whereas conventional-intensity thera…”
BackgroundResultBeyth, R. J., Quinn, L. M., & Landefeld, C. S. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00198-3 · Cited by 773
Research works printed but not linked: 3
- Kearon C, 2003, Circulation, 107, I
- 10.2307/2281868 · doi:10.2307/2281868 · Paper page
- Mantel N, 1966, Cancer Chemother Rep, 50, 163
Cited by
Items 501–600 of 748
Phospholipid inhibitors: State of the Art
Galli, M. (2011) · Hämostaseologie · doi:10.5482/ha-1165 · Cited by 6
Mearns, E. S., Hawthorne, J., Song, J.-S., & Coleman, C. I. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-005379 · Cited by 5
Jiang, R., Shi, Y., Zhang, R., Pudasain, B., Wang, L., Zhao, Q., Yuan, P., Guo, J., Zhu, C., & Liu, J. (2018) · The Clinical Respiratory Journal · doi:10.1111/crj.12795 · Cited by 4
Predictive ability of scores for bleeding risk in heart disease outpatients on warfarin in Brazil
Oliveira, J. A. D. Q., Ribeiro, A. L. P., Ribeiro, D. D., Junior, V. A. N., Rocha, M. O. D. C., & Martins, M. A. P. (2018) · PLoS ONE · doi:10.1371/journal.pone.0205970 · Cited by 4
Guías de práctica clínica sobre diagnóstico y manejo del tromboembolismo pulmonar agudo
(ESC), G. D. T. P. E. D. Y. M. D. T. P. A. D. L. S. E. D. C. (2008) · Revista Española de Cardiología · doi:10.1016/s0300-8932(08)75741-5 · Cited by 6
Mao, R. L., Ropars, T., Tromeur, C., Barnier, A., Hourmant, B., Guégan, M., Jiménez, D., Leroyer, C., Lacut, K., & Couturaud, F. (2021) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-021-02518-z · Cited by 4
Zakai, N. A., Walker, R. F., MacLehose, R. F., Koh, I., Alonso, Á., & Lutsey, P. L. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12575 · Cited by 4
Therapie der Beinvenenthrombose und der Lungenembolie
Schellong, S. (2011) · Der Internist · doi:10.1007/s00108-011-2868-6 · Cited by 4
Practical Challenges in the Management of Oral Anticoagulation
Kayser, S. R. (2005) · Progress in Cardiovascular Nursing · doi:10.1111/j.0889-7204.2005.04029.x · Cited by 4
Pulmonary embolism: Current treatment options
Meysman, M., & Haentjens, P. (2005) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-005-0034-y · Cited by 4
Reiffel, J. A. (2010) · Europe PMC (PubMed Central) · doi:10.4022/jafib.304 · Cited by 4
Vitamin K Antagonists and Direct Thrombin Inhibitors: Present and Future
Pineo, G. F., & Hull, R. D. (2005) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2004.09.006 · Cited by 6
Kearon, C., Kovacs, M. J., & Julian, J. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66858-4 · Cited by 4
Self-citationDuration of Anticoagulant Therapy after Initial Idiopathic Venous Thromboembolism
Frazee, L. A., & Chomo, D. L. (2003) · Annals of Pharmacotherapy · doi:10.1345/aph.1c486 · Cited by 4
Duration of anticoagulant therapy for patients with venous thromboembolism
Garcia, D. A. (2008) · Thrombosis Research · doi:10.1016/j.thromres.2008.08.019 · Cited by 4
Reduced-Intensity Rivaroxaban for the Prevention of Recurrent Venous Thromboembolism
Crowther, M. A., & Cuker, A. C. (2017) · New England Journal of Medicine · doi:10.1056/nejme1701628 · Cited by 4
Self-citationDuration of Anticoagulation Following Venous Thromboembolism: A Meta-analysis
Ost, D., Tepper, J., Mihara, H., Lander, O., Heinzer, R., & Fein, A. (2005) · JAMA · doi:10.1001/jama.294.6.706 · Cited by 3
Durée optimale du traitement anticoagulant au décours d’une maladie veineuse thrombo-embolique
Savina, E. N., & Couturaud, F. (2011) · Journal des Maladies Vasculaires · doi:10.1016/s0398-0499(11)70005-1 · Cited by 3
Boureka, E., Ralli, E.-E., Arvanitaki, A., Lefkou, E. E., Fragakis, N., Giannakoulas, G. A., Mamopoulos, A. M., Dagklis, T., & Tsakiridis, I. G. (2025) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0000000000001407 · Cited by 3
Duration of anticoagulation treatment in patients with venous thromboembolism.
Kaatz, S., Qureshi, W., Fain, C., & Paje, D. G. (2010) · PubMed · Cited by 3
Weyland, P. (2009) · The Nurse Practitioner · doi:10.1097/01.npr.0000346589.28196.ec · Cited by 3
Piazza, G., & Goldhaber, S. Z. (2009) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2008.12.001 · Cited by 3
Pharmacological management of pulmonary embolism
Gouin, B., Robert‐Ebadi, H., Righini, M., & Blondon, M. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1268122 · Cited by 3
Strategien zur Antikoagulation bei Patienten mit tiefer Beinvenenthrombose und Lungenarterienembolie
Radke, P. W., & Möckel, M. (2017) · Herz · doi:10.1007/s00059-017-4655-1 · Cited by 3
Yeung, L., Miraflor, E. J., & Harken, A. H. (2012) · Surgery · doi:10.1016/j.surg.2012.09.008 · Cited by 3
Liem, T. K., & DeLoughery, T. G. (2013) · BMJ Evidence-Based Medicine · doi:10.1136/eb-2013-101317 · Cited by 3
Couma-Gen: Implications for Future Randomized Trials of Pharmacogenetic-Based Warfarin Therapy
Lesko, L. J., & Gage, B. F. (2008) · Personalized Medicine · doi:10.2217/17410541.5.2.163 · Cited by 3
“For future studies, patient total time in range (PTTR) may be a preferred end point because of its strong association with adverse events: patients with subtherapeutic INR values are at increased risk of thrombosis [13,14] and patients with high INR values are at increased risk of hemorrhage [15–17], although the risk…”
BackgroundTreatment strategies for acute pulmonary embolism
Blondon, M., Bounameaux, H., & Righini, M. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560902911470 · Cited by 3
“Although a reduction in the bleeding risk was expected, the ELATE study did not show any difference in clinically important bleeding between low-intensity and standard anticoagulation [22].”
ResultWeitz, J. I. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1604-7.00098-1 · Cited by 3
Self-citationFayol, A., Lanéelle, D., Hoffmann, C., Mahé, G., & Mahé, I. (2019) · VASA · doi:10.1024/0301-1526/a000789 · Cited by 3
Extended oral anticoagulation after incident venous thromboembolism – a paradigm shift?
Albertsen, I. E., Piazza, G., Søgaard, M., Nielsen, P. B., & Larsen, T. B. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1755260 · Cited by 3
“0 is more effective than placebo in reducing recurrence risk but do not reduce recurrence risk as effectively as standard INR range 2–3 and do not lead to lower bleeding risk [23,24].”
BackgroundRahmatini, R., Aliska, G., Usman, E., Yanni, M., & Ilmiawati, C. (2020) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2020.3436 · Cited by 3
Sciascia, S., Radin, M., & Schreiber, K. I. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23947-2.00045-x · Cited by 3
Tratamiento de la trombosis venosa profunda iliofemoral y del síndrome postrombótico
Botella, F. G., Gómez, M. L., Portolés, O., & Gadea, L. I. (2013) · Angiología · doi:10.1016/j.angio.2013.05.005 · Cited by 4
Hyers, T. M., Shetty, H. G. M., & Campbell, I. A. (2010) · The Journal of the Royal College of Physicians of Edinburgh · doi:10.4997/jrcpe.2010.310 · Cited by 3
Ansell, J. (2006) · Elsevier eBooks · doi:10.1016/b978-0-7216-0284-4.50059-2 · Cited by 3
Pulmonary Embolism and Deep Vein Thrombosis
Goldhaber, S. Z., & Piazza, G. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0101-8.00038-2 · Cited by 5
Comments on the 2014 ESC Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism
SEC Working Group for the ESC 2014 Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism, Embolism, E. R. F. T. E. 2. G. O. T. D. A. M. O. A. P., & SEC Clinical Practice Guidelines Committee (2014) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2014.11.003 · Cited by 11
Venous Disease and Pulmonary Embolism
Moneta, G. L., & Foley, M. I. (2008) · Springer eBooks · doi:10.1007/978-0-387-68113-9_68 · Cited by 3
Pharmacogenetics in Cardiovascular Disorders: An Update on the Principal Drugs
Predazzi, I. M., Mango, R., Norata, G. D., Daniele, N. D., Sergi, D., Romeo, F., & Novelli, G. (2013) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-013-0020-9 · Cited by 4
Kovacs, M. J. (2006) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-006-5577-6 · Cited by 3
“Hence, the ELATE study was designed to demonstrate that oral anticoagulant therapy with warfarin given at an INR intensity of 1.5‐1.9 would have equivalent efficacy but improved safety compared to standard intensity [ 8 ].”
BackgroundInfluentialSelf-citationStefanacci, R. G. (2005) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2005.09.001 · Cited by 3
The Treatment of Deep Venous Thrombosis, Including the Newer Agents
Rectenwald, J. E., & Wakefield, T. W. (2005) · Disease-a-Month · doi:10.1016/j.disamonth.2005.03.004 · Cited by 3
Couturaud, F., & Kearon, C. (2008) · Revue de Pneumologie Clinique · doi:10.1016/j.pneumo.2008.09.007 · Cited by 4
Self-citationTreatment and Long-Term Management of Venous Thromboembolism
AlBadri, A., & Spyropoulos, A. C. (2014) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2014.06.011 · Cited by 3
Thrombotic complications and thromboprophylaxis in breast and gynaecological malignancies
Goyal, D., Choudhury, A., & Lip, G. Y. H. (2005) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/00001703-200502000-00004 · Cited by 3
Extended Anticoagulation Therapy for the Primary and Secondary Prevention of Venous Thromboembolism
Blanchard, E. M., & Ansell, J. (2005) · Drugs · doi:10.2165/00003495-200565030-00001 · Cited by 3
Current and emerging options in the management of venous thromboembolism.
Jaffer, A. K., Brotman, D. J., & Michota, F. A. (2005) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.72.suppl_1.s14 · Cited by 3
Therapeutic Update on the Prevention and Treatment of Venous Thromboembolism
McGuire, M., & Dobesh, P. P. (2004) · Journal of Pharmacy Practice · doi:10.1177/0897190004271779 · Cited by 3
“9 (low intensity).(130) Patients were followed for an average of 2.”
BackgroundThe Pharmacogenetics of Vitamin K Antagonist Anticoagulation Drugs
Eby, C. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-283-4_8 · Cited by 2
“There is evidence to support associations between bleeding complications and elevated INRs [79, 80], and thrombosis and lower INRs [81].”
BackgroundYamaguchi, J., Makino, K., Kusunose, Y., Higa, S., Takagi, T., Suzuki, K., & Lee, T. (2013) · Journal of Cardiology Cases · doi:10.1016/j.jccase.2013.05.002 · Cited by 2
“[4] Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells P, Julian JA, MacKinnon B, Weitz JI, Crowther MA, Dolan S, Turpie AG, Geerts W, Solymoss S, van Nguyen P, Demers C, et al.”
BackgroundSafety and Efficacy of Argatroban in the Management of Heparin-Induced Thrombocytopenia
Saugel, B., Schmid, R. M., & Huber, W. (2011) · Clinical Medicine Insights Blood Disorders · doi:10.4137/cmbd.s5118 · Cited by 2
Parameshwar, S., Rashmi, R., & Dattatreya, V. (2016) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20161771 · Cited by 2
Treatment of Acute Venous Thromboembolism
Nair, S. N., Garza, N., George, M., & Kaatz, S. (2020) · Medical Clinics of North America · doi:10.1016/j.mcna.2020.03.004 · Cited by 3
Sae-Lim, P., & Saelue, P. (2025) · Scientific Reports · doi:10.1038/s41598-025-08229-2 · Cited by 3
“However, some studies have reported a high risk of recurrent VTE in patients undergoing low-intensity warfarin therapy 31,32 .”
Jiménez, D., & Uresandi, F. (2014) · Angiología · doi:10.1016/j.angio.2014.02.003 · Cited by 3
Posadas‐Martínez, M. L., Pagotto, V. L., Ratti, M. F. G., Alfie, V., Andresik, D., Gómez, F. T., Giunta, D. H., Luxardo, R., Scolnik, M., & Vázquez, F. J. (2020) · Revista de la Facultad de Ciencias Médicas de Córdoba · doi:10.31053/1853.0605.v77.n3.27135 · Cited by 2
Groat, D., Martin, K. A., Rosovsky, R. P. G., Sanfilippo, K. M., Gaddh, M., Kreuziger, L. B., Federici, E. H., & Woller, S. C. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm13010096 · Cited by 2
“, we present the results of a survey that shows internal medicine physician and primary care clinician decision-making when considering dose reduction of apixaban and compared with usual care intensity has been found to reduce efficacy without a reduction in bleeding risk [20].”
BackgroundA Novel Nomogram for Predicting Warfarin-Related Bleeding: A Retrospective Cohort Study
Yang, S., & Yao, W. (2024) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296241234894 · Cited by 2
Fu, X., Ren, H., Yang, Y., Niu, Z., & Zhang, L. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1618626 · Cited by 2
Sobreanticoagulación con Warfarina
Ruiz, J. C. P. (2009) · Archivos de Medicina (Manizales) · doi:10.30554/archmed.9.2.1316.2009 · Cited by 2
The Role of Oral Direct Thrombin Inhibitors in the Treatment of Venous Thromboembolism
Busti, A. J., & Bussey, H. I. (2004) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.15.184s.43163 · Cited by 2
Managing anticoagulant related coagulopathy
Jaffer, A. K. (2007) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-007-0107-8 · Cited by 2
Hwang, J. M., Taylor, T. N., Sharma, K. P., Clemente, J. L., & Garwood, C. L. (2011) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-011-0643-0 · Cited by 2
Nuevas estrategias en la prevención secundaria de la recurrencia de la tromboembolia venosa
Lecumberri, R., Feliu, J., & Rocha, E. A. V. (2005) · Medicina Clínica · doi:10.1016/s0025-7753(05)72176-x · Cited by 2
Venous thromboembolism: Diagnosis, treatment and the prevention of long-term complications
Barnes, G. D., Froehlich, J. B., Kanthi, Y. M., & Wakefield, T. W. (2014) · Reviews in vascular medicine · doi:10.1016/j.rvm.2014.07.005 · Cited by 2
Treatment of Cancer-Associated Venous Thrombosis
Sluis, G. L. V., & Buller, H. R. (2009) · Cancer Investigation · doi:10.1080/07357900802656483 · Cited by 2
“Vitamin K antagonists are very effective and the risk of recurrence gets reduced by approximately 90% during the treatment (21, 22).”
BackgroundManaging Extended Oral Anticoagulation After Unprovoked Venous Thromboembolism
Joseph, L., & Bartholomew, J. R. (2016) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248416652236 · Cited by 2
“0, as reported in the ELATE trial.(15) Despite lower recurrence rates during extended anticoagulant treatment, VKA therapy does not confer additional clinical advantage after its discontinuation.”
BackgroundIs it reasonable to use a lower DOACs dose in some patients with VTE? Yes
Imberti, D., & Mastroiacovo, D. (2017) · Internal and Emergency Medicine · doi:10.1007/s11739-017-1688-7 · Cited by 2
“Low-intensity warfarin therapy has been proposed as secondary prophylaxis after a median period of 6 months [14] or after 3 or more months [15] of full dose anticoagulant therapy in patients with a previous VTE.”
BackgroundMorris, T. A., & Fedullo, P. F. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-3383-5.00057-9 · Cited by 4
Pulmonary embolism in the emergency department: A Singaporean nursing case review
Tan, Y., & Christensen, M. (2012) · Intensive and Critical Care Nursing · doi:10.1016/j.iccn.2012.04.001 · Cited by 2
Eriksson, H. (2004) · Drugs · doi:10.2165/00003495-200464001-00006 · Cited by 2
“The authors also stated that, collectively, the results of the ELATE [33] and PREVENT [32] studies, and those of another trial investigating extended treatment of patients with idiopathic venous thromboembolism, [24] suggest that long-term low-intensity warfarin reduces the risk of recurrent thrombosis by about 75%, w…”
MethodResultInfluentialThrombose veineuse : diagnostic et traitement
Delsart, D., Girard, G., Moulin, N., Rivron-Guillot, K., & Decousus, H. (2007) · EMC - Médecine d urgence · doi:10.1016/s1959-5182(07)73324-x · Cited by 2
Current Treatment of Acute Lower Extremity Deep Venous Thrombosis
Janjigian, M. P., & Muhs, B. E. (2008) · The International Journal of Lower Extremity Wounds · doi:10.1177/1534734608314566 · Cited by 2
“The rates of recurrent VTE are significantly increased in patients suffering from one of the thrombophilic states.(8) After presenting with an initial PE, recurrence of VTE is manifested as a subsequent PE in ≈60% of episodes, whereas initial DVT recurs as DVT in ≈80% of episodes.”
BackgroundInfluentialTossing a coin or using common sense
Schulman, S. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12133 · Cited by 3
Martínez, J. L. A., Guillén, M. L. A., Remírez, M. S., Frías, M. T. Á., Dubois, J. G., & García, L. M. (2005) · Anales de Medicina Interna · doi:10.4321/s0212-71992005000400005 · Cited by 2
ten Cate‐Hoek, A. J., & Prins, M. H. (2004) · Current Opinion in Hematology · doi:10.1097/01.moh.0000130316.41033.e9 · Cited by 2
Ong, P. Y. S., Koomanan, N., Cheen, M. H. H., Lai, Y. F., Lim, S. H., Kong, M. C., & Ng, H. J. (2015) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029615598220 · Cited by 2
“0 were associated with poorer efficacy, with no significant improvements in safety in clinical studies.(13,14) Alternatively, a narrow INR target range that falls within the lower spectrum of the conventional INR target range might improve the safety profile of anticoagulation, without compromising efficacy.”
BackgroundPulmonary Complications of Hematologic Diseases
Machado, R. F., & Gladwin, M. T. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-3383-5.00094-4 · Cited by 2
Diagnóstico y tratamiento de la trombosis venosa profunda
Páramo, J. A., de Gaona, E. R., García, R., Rodríguez, P., & Lecumberri, R. (2017) · Revista de medicina de la Universidad de Navarra · doi:10.15581/021.7670 · Cited by 2
Bleeding Due to Warfarin Treatment: Five Years of Experience
Koçak, S., Ertekin, B., Öztürk, E., Dündar, Z. D., Acar, T., & Girişgin, A. S. (2019) · Turkiye Klinikleri Cardiovascular Sciences · doi:10.5336/cardiosci.2019-65895 · Cited by 2
Betancourt, M. T., & Rodger, M. A. (2007) · Acta chirurgica Belgica · doi:10.1080/00015458.2007.11680138 · Cited by 2
Self-citationMenstrual Cessation in Females with Intellectual Disabilities: An Ethical Dilemma
Trigunait, P., & Sharmila, V. (2023) · Apollo Medicine · doi:10.4103/am.am_41_23 · Cited by 2
“[16] These findings suggest that health‑care providers should consider the potential risks and benefits of using OCs in these patient populations.”
Hereditary and Acquired Thrombophilia
Riess, H. B. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-287-8_15 · Cited by 2
Polymorphisms in interstitial lung diseases : friend or foe?
Wijnen, P. A. H. M. (2011) · Research Publications (Maastricht University) · doi:10.26481/dis.20110318pw · Cited by 2
Traitement de la maladie thromboembolique veineuse
Sanchez, O., Wermert, D., Allain, Y., Sors, H., & Meyer, G. (2005) · La Presse Médicale · doi:10.1016/s0755-4982(05)84204-6 · Cited by 2
Can anticoagulant treatment be tailored with biomarkers in patients with venous thromboembolism?
Kamphuisen, P. W. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.01931.x · Cited by 2
Low intensity warfarin: is it clinically useful in venous thromboembolism management?
Bauer, K. A. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05174.x · Cited by 2
“…2004 Blackwell Publishing Ltd, British Journal of Haematology, 127, 155–158 doi:10.1111/j.1365-2141.2004.05174.x Low-Intensity Anticoagulation for Thromboembolism (ELATE) trial compared INR intensities of 1Æ5–1Æ9 and 2Æ0–3Æ0 in 738 patients (Kearon et al, 2003).”
BackgroundInfluentialTrombosis venosa profunda: consideraciones terapéuticas
Vicente, V., & Almela, M. L. L. (2005) · Revista Clínica Española · doi:10.1157/13070750 · Cited by 2
Finucane, K., & Archer, C. B. (2008) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.2007.02637.x · Cited by 2
Hann, C. L., & Streiff, M. B. (2007) · Elsevier eBooks · doi:10.1016/b978-141602401-9.10031-8 · Cited by 2
Bleeding risk score: limits and practicability
Morrone, D., & Caterina, R. D. (2021) · Heart · doi:10.1136/heartjnl-2021-320172 · Cited by 2
Anticoagulant Treatment of Deep Vein Thrombosis and Pulmonary Embolism
Tran, H. A., McRae, S. J., & Ginsberg, J. S. (2006) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2005.09.004 · Cited by 1
Self-citationKeller, K., Schmitt, V. H., Ostad, M. A., Münzel, T. F., Hobohm, L., & Espinola–Klein, C. (2022) · The Clinical Respiratory Journal · doi:10.1111/crj.13571 · Cited by 1
Pronostic et suivi à long terme de la maladie thromboembolique veineuse
Pinède, L. (2007) · Archives des Maladies du Coeur et des Vaisseaux - Pratique · doi:10.1016/s1261-694x(07)92132-x · Cited by 1
Clasificación y tratamiento de la embolia pulmonar aguda
Gabriel, F., Labiós, M., Ferreres, J., & Ibáñez, L. (2013) · Angiología · doi:10.1016/j.angio.2012.12.002 · Cited by 1
Extended Therapy for Primary and Secondary Prevention of Venous Thromboembolism
Conway, S. E., & Marcy, T. R. (2010) · Journal of Pharmacy Practice · doi:10.1177/0897190010366930 · Cited by 1
Watson, H. G. (2012) · Evidence-Based Nursing · doi:10.1136/eb-2012-100896 · Cited by 1
“5–2) showed that although there appeared to be a benefit for low intensity warfarin it was inferior to conventional intensity warfarin with no reduction in major bleeding.(3) 4”
BackgroundTreatment of pulmonary embolism
Decousus, H., Mismetti, P., Couturaud, F., Ageno, W., & Bauersachs, R. M. (2015) · La Presse Médicale · doi:10.1016/j.lpm.2015.10.008 · Cited by 1
Long-term therapy of pulmonary embolism.
Agnelli, G., & Becattini, C. (2005) · PubMed · Cited by 1
Metadata
- Authors
- Kearon, C., Ginsberg, J. S., Kovacs, M. J., Anderson, D. R., Wells, P., Julian, J. A., MacKinnon, B., Weitz, J. I., Crowther, M. A., Dolan, S., Turpie, A. G., Geerts, W., Solymoss, S., van Nguyen, P., Demers, C., Kahn, S. R., Kassis, J., Rodger, M., Hambleton, J., & Gent, M.
- Affiliations
- McMaster University (CA)
- Western University (CA)
- Dalhousie University (CA)
- University of Ottawa (CA)
- University of New Brunswick (CA)
- University of Toronto (CA)
- McGill University (CA)
- Université Laval (CA)
- Université de Montréal (CA)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-08-14
- Volume
- 349
- Issue
- 7
- Pages
- 631-639
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2009013630
- Cited by
- 751
- References
- 12
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 3 · 2023: 12 · 2022: 8 · 2021: 12 · 2020: 17 · 2019: 25 · 2018: 38 · 2017: 26 · 2016: 29 · 2015: 27 · 2014: 31 · 2013: 58 · 2012: 45
- FWCI
- 34.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- warfarin, low-intensity anticoagulation, venous thromboembolism, recurrent venous thromboembolism, unprovoked venous thromboembolism, international normalized ratio, bleeding risk, anticoagulation intensity, long-term prophylaxis
- MeSH terms
- Age Factors, Aged, Anticoagulants, Double-Blind Method, Drug Administration Schedule, Female, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Pulmonary Embolism, Risk Factors, Warfarin, Treatment Outcome, International Normalized Ratio, Venous Thrombosis, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.